Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03047395 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,170
- Enrollment target
NCT03047395: Completed Phase 3 study, sponsored by AbbVie.
NCT03047395 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 2,170 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (181% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03047395, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,170 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
Primary Outcome
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospita
Interventions
- BIOLOGICAL risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,170 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2023-11-29 |
| Phase | Phase 3 |
What the finished NCT03047395 record still lists
NCT03047395 is an interventional study that assigns participants to a tested intervention. Its 2,170 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (181% higher).
The record links to 0 conditions, and to 1 intervention - of which risankizumab is the first listed.
NCT03047395 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03047395 about?
NCT03047395 is a clinical study titled "A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )". The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT03047395?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,170 participants. The study started on 2017-02-27. Estimated completion is 2023-11-29.
What interventions are being tested in trial NCT03047395?
The interventions under investigation include: risankizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03047395?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03047395's enrollment target sits among peer trials
2,170 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05742178 · 2,160 participants · NA
NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation
- NCT05917652 · 2,183 participants
The Actuate-CBC Study
- NCT06783335 · 2,150 participants
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
- NCT05805709 · 2,145 participants · NA
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI